In Brief: FDA Biological Response Modifiers Advisory Panel
This article was originally published in The Gray Sheet
Executive SummaryFDA Biological Response Modifiers Advisory Panel: Discussion of extracorporeal liver assist devices will be part of a panel meeting July 13-14 on public health concerns of xenotransplantation. Topics also will include the utility of "polymerase chain reaction in the clinical trials of biological therapies for hepatitis C." Meetings on both days will commence at 8 a.m. and take place at the Holiday Inn in Bethesda, Maryland. For more information, contact William Freas or Pearline Muckelvene at 301/827-0314...
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.